Kyntra Bio (KYNB) Total Liabilities (2014 - 2026)
Kyntra Bio (KYNB) posted Total Liabilities of $118.9 million for Q1 2026, up 3.3% sequentially from $115.1 million in Q4 2025, and down 65.04% YoY from $340.1 million in Q1 2025.
Kyntra Bio (KYNB) Total Liabilities (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Total Liabilities for 13 years, with the latest figure at $118.9 million in Q1 2026.
- Quarterly Total Liabilities fell 65.04% year-over-year to $118.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.9 million (down 65.04% YoY) and the FY2025 annual result came in at $115.1 million, down 71.09% from the prior year.
- Total Liabilities rose to $118.9 million in Q1 2026 per KYNB's latest filing, from $115.1 million in the prior quarter.
- Over five years, Total Liabilities peaked at $611.6 million in Q4 2022 and troughed at $115.1 million in Q4 2025.
- A 5-year average of $444.8 million and a median of $552.0 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities jumped 43.04% in 2022, then tumbled 74.36% in 2025.
- Over 5 years, Total Liabilities stood at $611.6 million in 2022, then retreated by 4.23% to $585.7 million in 2023, then sank by 32.02% to $398.2 million in 2024, then tumbled by 71.09% to $115.1 million in 2025, then gained by 3.3% to $118.9 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $118.9 million, $115.1 million, and $119.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Kyntra Bio | 29.83 Mn | 29.83 Mn | 1.47 Mn | 109.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 109.22 Mn |
| Mar 31, 2026 | 118.92 Mn |
| Dec 31, 2025 | 115.12 Mn |
| Sep 30, 2025 | 119.53 Mn |
| Jun 30, 2025 | 359.09 Mn |
| Mar 31, 2025 | 340.14 Mn |
| Dec 31, 2024 | 398.16 Mn |
| Sep 30, 2024 | 466.12 Mn |
| Jun 30, 2024 | 483.58 Mn |
| Mar 31, 2024 | 552.02 Mn |
| Dec 31, 2023 | 585.73 Mn |
| Sep 30, 2023 | 575.63 Mn |
| Jun 30, 2023 | 575.43 Mn |
| Mar 31, 2023 | 567.43 Mn |
| Dec 31, 2022 | 611.57 Mn |
| Sep 30, 2022 | 562.56 Mn |
| Jun 30, 2022 | 563.04 Mn |
| Mar 31, 2022 | 567.92 Mn |
| Dec 31, 2021 | 544.71 Mn |
| Sep 30, 2021 | 505.45 Mn |